H21F8-1 (ATCC® CRL-8018)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type:: hybridoma: B lymphocyte  /  Disease: hepatitis

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma: B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease hepatitis
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Derivation
Spleen cells were fused with P3-NSI/1Ag4-1 myeloma cells.
Genes Expressed
immunoglobulin; monoclonal antibody; against hepatitis B virus surface antigen (HBsAg)
Cellular Products
immunoglobulin; monoclonal antibody; against hepatitis B virus surface antigen (HBsAg)
Comments
Animals were immunized with hepatitis B virus surface antigen.
Spleen cells were fused with P3-NSI/1Ag4-1 myeloma cells.
Complete Growth Medium Iscove's modified Dulbecco's medium, 80%; fetal bovine serum, 20%
Subculturing
Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Isotype IgM
Name of Depositor Massachusetts General Hospital
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
References

Wands JR, Zurawski VR Jr.. Process for producing antibodies to hepatitis virus and cell lines therefor. US Patent 4,271,145 dated Jun 2 1981

Basic Documentation
References

Wands JR, Zurawski VR Jr.. Process for producing antibodies to hepatitis virus and cell lines therefor. US Patent 4,271,145 dated Jun 2 1981